Publications


Platform: Year: Target:

Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

International Association for the Study of Lung CancerDecember, 2023

Population Pharmacokinetic and Exposure-Response Safety Analyses of Mecbotamab Vedotin (BA3011) in Patients with Advanced Solid Tumors

ASCOMay, 2023

A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

American Association for Cancer ResearchApril, 2023

Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

Antibody Drug Conjugate SummitSeptember, 2022

Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma

Connective Tissue Oncology SocietyNovember, 2021

Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.

Alzheimer’s Association International ConferenceJuly, 2021

Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

Proceedings of the National Academy of SciencesJanuary, 2021

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2020

Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors

American Association for Cancer ResearchApril, 2020

Novel conditionally active biologic (CAB) antibodies

American Association for Cancer ResearchApril, 2019

A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate

American Society of Clinical OncologyJune, 2018

Anti-Tumor Efficacy of BA3021

American Association for Cancer ResearchApril, 2018

Anti-Tumor Efficacy of BA3011

American Association for Cancer ResearchApril, 2018

Novel Conditionally Active Biologic anti-Axl ADC Demonstrates Anti-Tumor Efficacy and Improved Safety Profile

American Association for Cancer ResearchApril, 2016